Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
批准号:
10015395
负责人:
DANIEL JANE-WIT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-10-01 至 2024-09-30
关键词:
AddressAffectAgonistAllograftingAntigen-Presenting CellsAreaAutologousB-LymphocytesBasic ScienceBiochemicalBiological AssayBlood VesselsBlood flowCD4 Positive T LymphocytesCaringCell ProliferationCell physiologyCellsChronicClinicalComplementComplement Membrane Attack ComplexComplicationDataDiagnosticDonor personEndothelial CellsErinaceidaeFDA approvedGraft SurvivalHealthHealth Services AccessibilityHealthcare SystemsHelper-Inducer T-LymphocyteHost DefenseHumanHypoxiaImmuneImmunoglobulin MImmunologyIn VitroInflammasomeInstitutesInterleukin-18IsoantibodiesKidney TransplantationLeadLesionLigandsLinkMediatingMedicalModelingMolecularNatural ImmunityOperative Surgical ProceduresOrgan TransplantationOutcomePathologicPathologic ProcessesPathologyPathway interactionsPatient-Focused OutcomesPatientsPeripheralPharmacologyPhosphorylationPopulationPostoperative PeriodProcessProductionPropertyProteinsReperfusion InjuryRespondentRiskRodentRoleSamplingSignal TransductionSiteSolidSpecimenSystemT-LymphocyteT-Lymphocyte SubsetsTestingTissuesTransplant RecipientsTransplantationVascular DiseasesVeteransWorkantibody-mediated rejectionbasecell injuryclinically relevantcostdelayed graft functiondonor-specific antibodyeffective therapygenetic approachhumanized mouseimplantationimprovedin vitro Modelin vivoinjuredisoimmunitymouse modelnovelphosphoproteomicsprospectiveresponsesmoothened signaling pathwayvascular inflammationwound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Ischemia reperfusion injury (IRI) is a pathological process affecting solid organ allografts and occurs
when a transplanted organ subjected to prolonged disruption of blood flow undergoes tissue damage following
surgical implantation. IRI frequently occurs among deceased donors and predisposes to chronic antibody-
mediated rejection (CABMR), decreased graft survival, and worsened patient outcomes. This condition has no
effective medical treatments and is especially relevant to veteran transplant recipients who undergo higher
rates of deceased donor transplants and are thus at risk for developing IRI and its related complications.
In recognition of the significant lifetime health burden and costs incurred by IRI to veteran patients and
to the VA Healthcare System, respectively, recent federal mandates have established mechanisms to
systemically improve care for veteran recipients of solid organ transplants, in particular renal transplants. This
mandate will increase the number of transplanting VA centers, institute systems-based changes to improve
pre- and post-operative access to care, and promote basic research to improve allograft survival.
In this context, we submit this transplant immunology application to explore a role for Hedgehog (Hh)
signaling in CABMR, an IRI-associated complication in solid organ transplantation. Complement (C') are
immune proteins involved in host defense that are pathologically activated on endothelial cells (ECs) during
IRI, a process we have found selectively expands T peripheral helper (TPH cells), a recently discovered CD4+ T
cell subset specialized in provision of B cell help. Hh signaling is a widely studied pathway regulating wound
healing by eliciting vascular cell proliferation. We reasoned that Hh ligands are released by C'-injured ECs
during IRI as a signal for autologous wound repair, but concurrently these same ligands could expand
alloimmune TPH cells that go on to promote alloantibody responses and CABMR-related pathologies.
To test this notion, we used humanized models in vitro and in vivo, and we used prospectively collected
patient samples to increase the clinical relevance of our findings. Our data showed that IRI-treated ECs
produced Hh ligands in a C'-dependent manner that selectively activated T peripheral helper (TPH) cells, a
newly described T cell subset specialized in provision of B cell help. Mechanistically, Hh induced ZFYVE21, a
novel Rab5 effector we discovered, to elicit Akt-mediated NRLP3 inflammasomes in TPH cells. This resulted in
IL-18 release and IL-18-mediated expansion of IL-18R1+TPH cells that promoted CABMR-like pathologies
including vascular inflammation, alloAb production, and vasculopathy. These exciting preliminary data address
an important and prevalent clinical problem that is a focus area of recent federal initiatives at the VA.
From these data, we hypothesize that Hedgehog ligands released by C'-injured EC during IRI activate
CD4+ TPH cells to elicit CABMR-associated pathologies. We will explore this hypothesis in 2 non-
interdependent Aims. In Aim 1, we will employ biochemical and functional assays to identify mechanisms(s) by
which Hh agonism activates a ZFYVE21-Akt-Casp1 axis to elicit inflammasome-dependent expansion of TPH
cells. We propose cutting edge approaches including phosphoproteomic analyses to facilitate mechanistic
discovery. In Aim 2, we will test the relevance of ZFYVE21-Akt-Casp1 signaling in vivo using 2 humanized
mouse models of CABMR, and we will test the clinical relevance of lead molecule(s) using prospectively
collected patient specimens. Our studies explore Hedgehog signaling as a new pathway that may be feasibly
modulated in clinical settings with recently FDA-approved agents to putatively block IRI-associated
complications like CABMR in solid organ transplantation. As such, findings from these studies may be relevant
for improving allograft survival in veteran patients who are at risk for IRI and its associated complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intracellular Membrane Attack Complexes and COVID-19 Immune Hyperactivation
-
批准号:10725199
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2023
-
负责人:DANIEL JANE-WIT
-
依托单位:
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
-
批准号:10514589
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:DANIEL JANE-WIT
-
依托单位:
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
-
批准号:10293588
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:DANIEL JANE-WIT
-
依托单位:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
-
批准号:10294356
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2018
-
负责人:DANIEL JANE-WIT
-
依托单位:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
-
批准号:9912195
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2018
-
负责人:DANIEL JANE-WIT
-
依托单位:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
-
批准号:10374856
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2018
-
负责人:DANIEL JANE-WIT
-
依托单位:
THE ROLE OF ZFYVE21 IN CEREBRAL AMYLOID ANGIOPATHY IN ALZHEIMER'S DISEASE
-
批准号:10288327
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2018
-
负责人:DANIEL JANE-WIT
-
依托单位:
Mechanisms of Non-Canonical NF-kB Activation in Transplant Arteriosclerosis
-
批准号:9376977
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2016
-
负责人:DANIEL JANE-WIT
-
依托单位:
Mechanisms of Non-Canonical NF-kB Activation in Transplant Arteriosclerosis
-
批准号:8805540
-
项目类别:
-
资助金额:$13.19万
-
财政年份:2015
-
负责人:DANIEL JANE-WIT
-
依托单位:
海外基金